References
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet2006; 368:1696–1705.
- Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther2005; 27:210–215.
- Cohen V, Teperikidis E, Jellinek SP, Rose J. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia. Clin Toxicol2008; 46:346–347.
- Summary of Product Characteristics: Victoza 6 mg/ml solution for injection in pre-filled pen. 2012. Available at: http://www medicines org uk/emc/medicine/21986. Accessed 19th November 2012.